By clicking Continue, you confirm that you are a healthcare professional In the UK.
▼This medicinal product is subject to additional monitoring. This will allow quick dentification of new safety information. You can help by reporting any side effects you may get.
If you get any side effects, talk to your healthcare professional. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.
A convenient option to ensure patients
administer DUPIXENT as directed1
An extensive Phase 3 clinical trial programme
DUPIXENT was studied in six Phase 3 clinical trials, in adults with moderate-to-severe atopic dermatitis (AD) including more than 2,400 adult patients worldwide, both as a monotherapy and with TCS for up to 52 weeks1
DUPIXENT was studied as a monotherapy, in 251 adolescents with moderate-to-severe AD inadequately controlled with topical treatment for up to 16 weeks2,3
DUPIXENT was studied with TCS in 367 severe AD children patients for up to 16 weeks compared to placebo with TCS4